Epigene Labs is creating intelligence-augmenting solutions for precision oncology research and drug development. Designed by cancer scientists for cancer scientists, the company’s mCUBE platform accelerates data-driven drug discovery, biomarker identification, and patient selection — to bring better treatments to patients faster. Based in Paris and Boston, Epigene Labs was initially incubated at the Harvard Innovation Labs and launched in France with the support of prominent European investors. Epigene Labs has partnerships with world-class cancer research institutes and biopharmaceutical companies, including Institut Curie, iTeos Therapeutics, Servier, and UCSF. mCUBE by Epigene Labs redefines target and patient selection, along with biomarker discovery and pre-clinical model selection, often reducing months of research to mere days. This platform, crafted specifically for oncology and immune-oncology research, offers a comprehensive suite of data science products and associated services that expedite multi-omic-driven drug discovery and development. To know more
